Berry Genomics, a Chinese prenatal genetic testing and diagnostics company backed by Qiming Venture Partners and Legend Capital, has completed a reverse merger with Shenzhen-listed Chengdu Tianxing Instrument & Meter in a deal that valued Berry at RMB4.3 billion (US$619 million).
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
